|
|
The long-chain n-3
fatty acids in fish have been demonstrated to
have antiarrhythmic properties in experimental
models and to prevent sudden cardiac death in a
randomized trial of post-myocardial infarction
patients. Therefore, we hypothesized that these
n-3 fatty acids might prevent potentially fatal
ventricular arrhythmias in high-risk patients.
Four hundred two patients with implanted
cardioverter/defibrillators (ICDs) were randomly
assigned to double-blind treatment with either a
fish oil or an olive oil daily supplement for 12
months. The primary end point, time to first ICD
event for ventricular tachycardia or
fibrillation (VT or VF) confirmed by stored
electrograms or death from any cause, was
analyzed by intention to treat. Secondary
analyses were performed for “probable”
ventricular arrhythmias, “on-treatment” analyses
for all subjects who had taken any of their oil
supplements, and “on-treatment” analyses only of
those subjects who were on treatment for at
least 11 months. Compliance with double-blind
treatment was similar in the 2 groups; however,
the noncompliance rate was high (35% of all
enrollees). In the primary analysis, assignment
to treatment with the fish oil supplement showed
a trend toward a prolonged time to the first ICD
event (VT or VF) or of death from any cause
(risk reduction of 28%; P=0.057). When therapies
for probable episodes of VT or VF were included,
the risk reduction became significant at 31%;
P=0.033. For those who stayed on protocol for at
least 11 months, the antiarrhythmic benefit of
fish oil was improved for those with confirmed
events (risk reduction of 38%; P=0.034).
Although significance was not achieved for the
primary end point, this study provides evidence
that for individuals at high risk of fatal
ventricular arrhythmias, regular daily ingestion
of fish oil fatty acids may significantly reduce
potentially fatal ventricular arrhythmias.
Circulation. 2005;112:2762-2768.
|